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Abstract
Background: Somatropin is recombinant human growth hormone (GH) used for the treatment of growth failure in
children and GH deficiency in adults. Two concentrations of a liquid formulation have been developed: 5.83 and
8.0 mg/mL. This trial compared the pharmacokinetics (PK), safety and tolerability of these two liquid concentrations
against the freeze-dried (FD) formulation in healthy volunteers.
Methods: In an open-label, single-centre, three-way crossover study, volunteers (aged 18-45 years) were given
subcutaneous injections of the reconstituted FD and two liquid formulations in random sequential order, each at 4
mg/dose, with a 1-week wash-out period between doses. To suppress endogenous GH secretion, intravenous
somatostatin was infused continuously 1 hour before to 24 hours after each dose, achieving a cumulative dose of
3 mg. Primary PK endpoints were area under the serum concentration-time curve (AUC0-t) and maximum serum
concentration (Cmax). For each of the two liquid formulations, bioequivalence with the FD formulation was
concluded if the 95% confidence intervals (CIs) for the estimated test/reference ratios of geometric means of AUC0-
t and Cmax were within the standard pre-specified acceptance range (0.80-1.25).
Results: Fifteen men and 15 women enrolled (safety population, n = 30; PK population, n = 28). Bioequivalence
with the FD formulation could be shown for both liquid formulations. The ratios of geometric means (95% CI)
were 1.046 (0.980, 1.117) and 0.991 (0.929, 1.058) for AUC0-t and 0.954 (0.875, 1.040) and 0.955 (0.876, 1.041) for
Cmax for the 5.83 and 8.0 mg/mL formulations, respectively. No significant differences between the three
treatments in half-lives, time to reach Cmax, clearance or volume of distribution were observed. After injection, the
most common side-effects were pain or injection-site reactions (all of mild intensity). There were no clinically
significant abnormal vital signs, ECG or laboratory findings. There were 56 treatment-related adverse events (AEs):
49 mild, 6 moderate and 1 severe (vomiting). No serious AEs occurred. The pattern of AEs was as expected and all
resolved by study end.
Conclusion: Both concentrations of a new liquid multi-dose formulation are bioequivalent to the FD reference
formulation and all are well tolerated.
Trial registration number: NCT01034735.
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Recombinant human growth hormone (r-hGH) is used for
the treatment of children with growth failure due to inade-
quate secretion of endogenous GH, gonadal dysgenesis
(Turner syndrome) or chronic kidney disease, and for
short children born small for gestational age. It is also
indicated for the treatment of GH deficiency (GHD) in
adults. Long-term treatment is effective at promoting
growth in GH-deficient children [1-7]. In a retrospective
survey of 631 children, r-hGH increased height by a mean
of approximately 8 cm per year over 2 years [3]. Similarly,
in an open-label study of 69 children with organic or idio-
pathic GHD, r-hGH was associated with a median growth
of 47.5 ± 8.5 cm over 7 years of treatment, with most sub-
jects reaching their predicted final height [1].
S a i z e n ®( M e r c kS e r o n oS . A .-G e n e v a ,S w i t z e r l a n d ,a n
affiliate of Merck KGaA, Darmstadt, Germany) r-hGH is
available as a freeze-dried (FD) multi-dose formulation
that needs to be reconstituted with bacteriostatic water
before use. Once reconstituted, it is administered from a
multi-dose cartridge, either by needle and syringe or by
needle-free jet injection. To eliminate this need for recon-
stitution, a ready-to-use liquid multi-dose formulation is
in development, which will avoid any risk of contamina-
tion or dilution errors during preparation and increase the
convenience of drug administration. Furthermore, increas-
ing the ease of injecting r-hGH may help to improve
adherence rates (although this has yet to be demonstrated
directly). Non-adherence is a problem with all long-term
treatments, and for children taking r-hGH manifests as a
lower growth rate in poorly compliant children compared
with children who miss fewer injections [3,8].
The new liquid formulation is being developed in two
concentrations: 5.83 and 8.0 mg/mL. This trial is the
first comparison of the pharmacokinetics (PK), safety
and tolerability of the two concentrations against the FD
formulation in healthy volunteers.
Methods
Participants
The study enrolled healthy male and female volunteers.
Eligible subjects were required to be aged 18-45 years;
have a body weight greater than 55 kg and a body mass
index (BMI) of > 20 and ≤ 30 kg/m
2; have vital signs
within the normal range; and to be either non-smokers
or smoke fewer than 10 cigarettes per day. Females
were also required to have a negative serum pregnancy
test within 3 weeks of the trial start and a negative
urine pregnancy test at the day before dosing. The fol-
lowing exclusion criteria were applied: a history or pre-
sence of cholelithiasis, diabetes, tumours in the pituitary
gland or hypothalamus, any serious allergy, positive ser-
ological test for hepatitis B or C and HIV, hypertension
or other significant cardiovascular abnormality. Subjects
were also excluded if they had a significant history or
clinical evidence of auto-immune, gastrointestinal, hae-
matological, haematopoietic, hepatic, neurological, pan-
creatic or renal disease, or had a positive drug or
alcohol test or chronic use of medication.
Study design
The single-centre trial (NCT01034735), carried out at a
clinical pharmacology research centre in Germany, had
an open, randomized, three-way crossover design. Treat-
ment with r-hGH (Saizen®; Merck Serono S.A. - Geneva)
started within 21 days of screening. Each volunteer
received three treatments: reconstituted FD (8.8 mg/1.51
mL) and two liquid formulations (5.83 and 8.0 mg/mL).
All three treatments were administered as a single sub-
cutaneous dose of 4 mg, to allow proper determination
of the PK parameters. The doses were administered in a
randomized sequence with a 1-week wash-out period
between each administration. The doses were injected
into the anterior abdominal wall, around the umbilicus
at the top of a skin fold, using a needle and syringe, and
were injected at a distance of at least 10 cm from one
another in pre-marked locations.
Additionally, intravenous somatostatin was infused
continuously from 1 hour before to 24 hours after each
d o s e ,a c h i e v i n gac u m u l a t i v ed o s eo f3m g .T h i sp i t u i -
tary down-regulation was necessary to suppress endo-
genous GH secretion in the healthy volunteers to allow
reliable calculation of PK parameters.
For each r-hGH administration, the subject attended
t h ec l i n i c a lu n i to nt h ed a yb e f o r et h es t u d yd r u g
administration (days -1, 7 and 14) and stayed in the unit
until 26 hours after drug administration (days 2, 9 and
16). Blood samples for PK analysis were taken hourly up
to 10 hours, and then at 12, 18 and 24 hours post-dose.
Vital signs, safety and tolerability were assessed before
and 24-26 hours after each dose and 14 ± 3 days after
the last dose.
The trial was conducted in compliance with the
Declaration of Helsinki and the ICH Guideline of Good
Clinical Practice, in addition to European, US and Ger-
man directives for proper conduct of clinical drug trials.
The study was approved by the national regulatory
agency (the Federal Institute for Drugs and Medicinal
Products [Bundesinstitut für Arzneimittel und Medizin-
produkte]) and the independent ethics committee of the
Bavarian Chamber of Physicians. Participants gave writ-
ten informed consent at the start of the trial.
Objectives
The primary objective of the study was to assess the
bioequivalence of two concentrations of the liquid
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mulation. The secondary objectives were to evaluate
safety and tolerability, and to describe the PK para-
meters of the liquid formulations of r-hGH in compari-
son with the FD formulation.
Outcomes measures
Primary PK endpoints were the area under the serum
concentration-time curve from time 0 to the last mea-
surable concentration time point after drug administra-
tion (AUC0-t)a n dt h em a x i m u ms e r u mc o n c e n t r a t i o n
(Cmax). Secondary PK endpoints included the total area
under the serum concentration-time curve extrapolated
to infinity (AUC0-∞), time to reach Cmax (tmax), terminal
elimination half life (t1/2), apparent volume of distribu-
tion (Vz/f) and apparent clearance (CL/f).
Quantitative determination of r-hGH in human serum
samples was performed using a ‘two-step’ sandwich-type
immunoassay. The assay was fully validated according to
the FDA and EMA guidelines on bioanalytical method
validation and best practice recommendations for the
validation and implementation of quantitative bioanalyti-
cal methods [9-11]. The lower limit of quantification
(LLOQ) of the immunoassay was 0.4 ng/mL. The actual
administered dose was determined by gravimetric mea-
surement, subtracting the post-dose weight of the syr-
inge from the pre-dose weight and calculating with a
density of 1.02 g/mL for the 5.83 mg/mL liquid formula-
tion and FD formulation and 1.03 g/mL for the 8 mg/
mL liquid formulation.
Tolerability was assessed by adverse events (AEs)
queried on an ongoing basis from the day prior to dos-
ing to at least 14 ± 3 days after the last dose administra-
tion. Additionally, tolerability was evaluated immediately
pre-dose, at the time of administration (injection-site
reactions [ISRs] only), 5 minutes, and 2, 4, 6, 12 and 24
hours after each injection. ISRs were assessed by the
investigator, whereas itching at the injection site and
pain were assessed by the subject; a 100 mm visual ana-
logue scale (VAS) was used to assess pain.
Safety assessments comprisedp h y s i c a le x a m i n a t i o n ,
vital signs (blood pressure, pulse rate, body tempera-
ture), supine 12-lead ECG recordings and laboratory
tests. The physical examination was made at screening
and at 14 ± 3 days after each administration. Vital signs
were taken immediately pre-dose, 1, 6, 12 and 24 hours
after treatment administration, and at the post-study
visit. ECG measurements were taken before each dose.
Sample size
A total of 24 evaluable subjects (four subjects for each
treatment sequence) were required to provide approxi-
mately 90% power for demonstrating bioequivalence.
This calculation assumed intra-subject coefficients of
variation of approximately 12% for AUC and 17% for
Cmax, based on earlier studies with the FD formulation
and values between 0.95 and 1.05 for the true treatment
ratio test/reference. The 95% confidence level (CI) was
used to adjust for multiplicity. To account for potential
drop-outs, 30 subjects were enrolled.
Randomization
Subjects were randomly assigned in chronological order
to a treatment sequence, according to the randomization
list, with an equal number of subjects in each of the six
treatment sequences. Randomization of each subject to
a treatment sequence occurred immediately before dos-
ing on study day 1.
PK analysis and statistical methods
PK analyses were performed for the PK population and
the safety analyses were performed for the safety popu-
lation. The PK population included all subjects who had
been treated according to the protocol in all trial peri-
ods who fulfilled the following criteria: all inclusion/
exclusion criteria satisfied; adequate trial medication
compliance; absence of relevant protocol violations and
availability for the primary target variables for at least
one treatment. The safety population included all sub-
jects who received at least one dose of trial medication
and had follow-up safety data.
The PK parameters of r-hGH were calculated accord-
ing to non-compartmental standard methods using the
validated computer program KINETICA (Version 4.4.1,
Thermo, Philadelphia, USA). Statistical analysis was per-
formed using the computer program package SAS Sys-
tem for Windows (TM version 8.2; SAS Institute, Cary
NC, USA).
A mixed model was fitted to each of the log-trans-
formed PK endpoints, Cmax,A U C 0-t,C max adjusted to
target dose (Cmax adj)a n dA U C 0-t adjusted to target
dose (AUC0-t adj) with fixed effect terms for treatment,
period and sequence, and subject as a random effect. In
compliance with the relevant FDA and EMA guidelines
[9-11], for each of the two test liquid formulations, bioe-
quivalence was concluded if the 95% CIs for the esti-
mated test/reference ratios of geometric means of
AUC0-t and Cmax were within the standard pre-specified
acceptance range for bioequivalence (0.80-1.25). In addi-
tion, a further correction for the measured active con-
tent (as determined by the certificate of analysis of each
formulation) was applied to the ratio estimates and con-
fidence limits in order to further assess bioequivalence
(Table 1).
All PK parameters were presented in a descriptive way
per treatment group (number of subjects [n], mean,
standard deviation [SD], median, geometric mean, stan-
dard error of mean [SEM], coefficient of variation,
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serum concentrations were also described per time
point and treatment. Values below the LLOQ were
taken as zero for descriptive statistics of concentrations.
The numerical values for tolerability and safety vari-
ables were summarized descriptively for the safety
population.
Results
Participants
Fifteen men and 15 women were enrolled. Two subjects
dropped out at the time of check-in for the third period
due to non-adherence to protocol requirements. The
mean age of the volunteers was 31.8 years (range 18-45
years). At the pre-study examination, the mean weight was
70.4 kg (54.9-91.8 kg), BMI was 23.7 (20.1-28.7) and height
was 1.72 m (1.54-1.89 m). The characteristics of subjects
were similar across the treatment sequences: the mean age
range was 24.2-38.0 years, mean weight 65.0-76.5 kg and
mean BMI 23.0-24.8 kg/m
2, and the number of subjects
per sequence ranged between 1 and 4. In total, 21 volun-
teers were non-smokers and nine were smokers.
The PK population comprised 28 subjects, and all 30
subjects received at least one dose of trial medication,
so were included in the safety evaluation.
Pharmacokinetics
Bioequivalence to the FD formulation could be demon-
strated for both concentrations of the liquid-formulation
treatment as the 95% CI for the ratios of geometric
means for AUC0-t and Cmax fell within the acceptance
criteria of 0.80-1.25. The actual dose of the treatments
administered varied slightly between the FD formulation
and the two concentrations of the liquid formulation
(Table 1). However, adjustments for actual dose
administered, active content, or both, further supported
the conclusion of bioequivalence (Table 2).
All pre-dose serum samples had concentrations of GH
below the LLOQ. Overall, the PK parameters of the two
strengths of liquid formulation and the FD formulation
of r-hGH showed low variability. There were no signifi-
cant differences between the three treatments in half-
lives (t1/2), time to reach Cmax (tmax), clearance (CL/f) or
volume of distribution (Vz/f) (Table 3). The least squares
geometric means in Table 2 are derived from the mixed
model. They deviate very slightly from the ordinary geo-
metric means in Table 3, therefore. The mean concen-
tration-time profiles showed low and similar intra-
subject variability and were close to superimposable for
the three treatments (Figure 1).
Tolerability and safety
Twenty-six subjects (87%) reported pain after drug
administration. Most of the episodes were very mild,
with a mean intensity of only 3.52 mm on the 100 mm
VAS and a maximum of 29 mm. The pain typically
resolved within 5 minutes of injection.
A total of 31 ISRs occurred in 19 subjects (Table 4).
Reactions comprised redness, bruising and itching. Four-
teen, eight and nine ISRs occurred after treatment with
the 5.83 mg/mL liquid, 8.0 mg/mL liquid and FD for-
mulations, respectively. Twenty-six of the reactions were
recorded 5 minutes post-dose. All reactions were mild,
with no local reactions considered moderate or severe.
AEs were experienced by 26/30 (87%) subjects. There
were 95 AEs overall (four pre-dose) with 56 considered
as treatment-related (Table 5). Of the treatment-related
AEs, 49 were mild in intensity, with only six instances
of moderate AEs and one case of severe vomiting. There
were no serious or life-threatening AEs and all events
resolved by the end of the study.
There were no clinically significant abnormal vital
signs or ECG results. All laboratory values were within
the reference range or were judged by the investigator
not to be clinically relevant.
Discussion
This study has shown that both concentrations of a new
liquid formulation were bioequivalent to the FD refer-
ence formulation in healthy volunteers with pituitary
somatrope cell down-regulation. This conclusion is
robust to adjustments to each subject’s actual dose and
to adjustments for active content. There were no appar-
ent differences between the two liquid formulations of
r-hGH and the FD formulation in the rate and extent of
drug exposure, half-life, clearance or volume of distribu-
tion. In addition, variability in the PK parameters was
low across the three treatments.
Table 1 Actual dose and summary of calculation of active
content as a percentage of target (n = 28,
pharmacokinetic population)
Parameter Formulation
ABC
Actual dose (geometric mean [CV%]
mg)
3.695
(3.26)
3.591
(2.92)
3.662
(3.95)
Active content (AC), mg 6.0 7.7 8.2
Container volume (V), mL 1.03 1.0 -
Concentration (AC/V), mg/mL 5.825 7.7 5.43
Target concentration (T), mg/mL 5.83 8.0 -
Percentage of target concentration
A and B: 100 × [AC/V]/T
C: 100 × [AC/T]
99.92 96.25 93.18
CV, coefficient of variation; r-hGH, recombinant human growth hormone.
A = r-hGH liquid multi-dose, 5.83 mg/mL; injection of 0.686 mL.
B = r-hGH liquid multi-dose, 8.0 mg/mL; injection of 0.5 mL.
C = r-hGH freeze-dried 8.8 mg, reconstituted in 1.51 mL; injection of 0.686 mL.
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tions is not assumed to be significantly influenced by
characteristics of the study population. Because of this,
data from healthy volunteers can be extrapolated to
adult as well as child patients.
The r-hGH liquid multi-dose and the r-hGH FD for-
mulations were administered at a dose of 4 mg. This
dose level is far higher than the recommended therapeu-
tic dose in adults (which is started at 0.15-0.3 mg/day
and seldom exceeds 1.0 mg/day) or children (which
does not exceed 0.05 mg/kg body weight/day) [12], but
was chosen to allow accurate determination of GH PK
parameters. Pituitary down-regulation was also necessary
to suppress endogenous GH secretion in the healthy
volunteers and to reliably calculate the PK parameters.
The dose of 3 mg somatostatin in 25 hours was based
on previous experience [13,14] and was also higher than
therapeutic doses (which do not usually exceed 0.6 mg/
day for adults [15,16]).
Table 2 Estimates with 95% confidence intervals for ratios of geometric means in pharmacokinetic (PK) parameters of
recombinant human growth hormone (r-hGH) in serum (n = 28, PK population)
Statistic Formulation AUC0-t, ng/mL*h Cmax, ng/mL AUC0-t adj, ng/mL*h Cmax adj, ng/mL
Adjusted for actual dose
Least squares geometric mean A 293.1 39.52 317.4 42.80
B 277.7 39.57 309.5 44.09
C 280.1 41.43 306.1 45.26
CV% 12.2 16.2 12.3 16.2
Ratio estimate (95% CI) A/C 1.05
(0.98, 1.12)
0.95
(0.88, 1.04)
1.04
(0.97, 1.11)
0.95
(0.87, 1.03)
B/C 0.99
(0.93, 1.06)
0.96
(0.88, 1.04)
1.01
(0.95, 1.08)
0.97
(0.89, 1.06)
Ratio estimate (95% CI) (corrected for active content) A/C
a 0.98
(0.91, 1.04)
0.89
(0.82, 0.97)
0.97
(0.91, 1.03)
0.88
(0.81, 0.96)
B/C
b 0.96
(0.90, 1.02)
0.93
(0.85, 1.01)
0.98
(0.92, 1.05)
0.94
(0.87, 1.03)
aCorrection factor: 93.18/99.9;
bCorrection factor: 93.18/96.25.
A = r-hGH liquid multi-dose, 5.83 mg/mL.
B = r-hGH liquid multi-dose, 8.0 mg/mL.
C = r-hGH freeze-dried 8.8 mg, reconstituted in 1.51 mL.
AUC0-t, area under the serum concentration-time curve from time 0 to the last measurable concentration time point after drug administration; Cmax, maximum
serum concentration; CI, confidence interval;
CV, coefficient of variation.
Table 3 Pharmacokinetic (PK) parameters of recombinant
human growth hormone (r-hGH) in serum (n = 28, PK
population)
Parameter Formulation
ABC
AUC0-t, ng/mL*h 295 (23.1)
191-474
279 (26.2)
120-381
281 (23.6)
165-411
Cmax, ng/mL 39.8 (28.0)
21.9-70.9
39.8 (31.6)
18.9-67.8
41.6 (31.1)
18.4-75.6
AUC0-∞, ng/mL*h 306 (23.3)
200-480
291 (24.2)
135-386
291 (23.3)
170-418
tmax, h 4.0
2.0-7.0
4.0
2.0-6.0
4.0
2.0-6.0
t1/2, h 2.19 (32.0)
1.24-5.38
2.22 (27.2)
1.42-4.11
2.05 (30.2)
1.18-3.85
Vz/f, L 41.2 (41.3)
18.3-117.9
44.0 (45.3)
24.2-132.5
40.7 (40.5)
19.8-90.6
CL/f, L/h 13.1 (23.3)
8.3-20.0
13.7 (24.2)
10.4-29.5
13.8 (23.3)
9.6-23.5
Geomean (geo CV%) and range, for tmax median and range are given.
AUC0-t, area under the serum concentration-time curve from time 0 to the last
measurable concentration time point after drug administration; AUC0-∞, total
area under the serum concentration-time curve extrapolated to infinity; Cmax,
maximum serum concentration; CL/f, apparent clearance; CV, coefficient of
variation; t1/2, terminal elimination half life; tmax, time to reach Cmax;V z/f,
apparent volume of distribution.
A = r-hGH liquid multi-dose, 5.83 mg/mL.
B = r-hGH liquid multi-dose, 8.0 mg/mL.
C = r-hGH freeze-dried 8.8 mg, reconstituted in 1.51 mL.
Figure 1 Mean concentration-time profile of r-hGH in serum (n
= 28). Administered dose of 4 mg.
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AEs than expected in clinical practice. Most of the AEs
that were reported, including nausea, vomiting, head-
ache and dizziness, can be related to the somatostatin
infusion [1,2,12-16]. No serious AEs were reported. Both
test preparations were well tolerated with regard to local
site reactions, vital signs, ECG findings and laboratory
findings, as was the reference FD preparation. Post-
injection pain was mild and transient and any ISRs were
similarly low in intensity.
The label for the liquid r-hGH is expected to be the
same as for the FD r-hGH with the exception of the sto-
rage requirements. Although both the liquid and FD for-
mulations (before reconstitution) have a shelf life of
2 years, the liquid must be stored at 2-8°C, whereas the
FD formulation can be stored at < 25°C. The shelf-life
and storage conditions after the cartridges have started
to be used are the same across formulations: 21-28 days
at 2-8°C (depending on the local label). Both liquid
formulations will be available in 3 mL cartridges with
stability for at least 18 months at 2-8°C, allowing inter-
changeability between the electronic and needle-free
delivery devices. It is hoped that the simplification of
the injection or needle-free administration process pro-
vided by liquid r-hGH will make this treatment less of a
burden for patients. Increasing the ease of injecting r-
hGH may help to make treatment more convenient for
patients, thereby improving adherence rates.
Conclusion
The two strengths of the liquid multi-dose formulation
of r-hGH are bioequivalent to the FD multi-dose refer-
ence formulation and are well tolerated. This conclusion
is robust to adjustments for the active content and the
actual dose administered.
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